Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN R SARKISIAN

Allopathic & Osteopathic Physicians Ophthalmology Glaucoma Specialist

NPI
1386601318
CMS profile
335038
Location
OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$36,130.14

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN R SARKISIAN

NPI 1386601318 · CMS profile ID 335038

Allopathic & Osteopathic Physicians / Ophthalmology / Glaucoma Specialist

OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386601318?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN R SARKISIAN, NPI 1386601318, CMS profile ID 335038. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386601318?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STEVEN R SARKISIAN, NPI 1386601318, CMS profile ID 335038. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386601318?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STEVEN R SARKISIAN, NPI 1386601318, CMS profile ID 335038, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1386601318?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $36,130.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $22.2207/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828811 CMS
Alcon Vision LLC $3.0507/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650289 CMS
AbbVie Inc. $25.6007/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828808 CMS
Alcon Vision LLC $4.7907/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650323 CMS
Novartis Pharmaceuticals Corporation $13.0306/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993363085 CMS
AbbVie Inc. $21.8406/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828803 CMS
Alcon Vision LLC $21.0306/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650407 CMS
Alcon Vision LLC $4.7506/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650317 CMS
Novartis Pharmaceuticals Corporation $13.5005/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993363081 CMS
Glaukos Corporation $1,600.0005/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059857559 CMS
AbbVie Inc. $19.9705/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828801 CMS
Alcon Vision LLC $3.2105/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650295 CMS
Novartis Pharmaceuticals Corporation $15.5205/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993363069 CMS
Alcon Vision LLC $651.0005/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001560949 CMS
Alcon Vision LLC $651.0005/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001560963 CMS
Alcon Vision LLC $1,400.0005/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001560975 CMS
Alcon Vision LLC $3,500.0005/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001560993 CMS
Glaukos Corporation $800.0005/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059857557 CMS
Glaukos Corporation $160.4705/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059857561 CMS
AbbVie Inc. $4.3005/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828797 CMS
Alcon Vision LLC $21.7205/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650427 CMS
AbbVie Inc. $36.7905/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828793 CMS
AbbVie Inc. $9.8805/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828785 CMS
AbbVie Inc. $86.8605/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828789 CMS
Alcon Vision LLC $104.5705/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650463 CMS
Glaukos Corporation $1,600.0004/28/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059857555 CMS
AbbVie Inc. $5.4304/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828781 CMS
Alcon Vision LLC $18.5104/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650385 CMS
Bausch & Lomb Americas Inc. $24.4304/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037876127 CMS
RxSight Inc $28.9004/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060181813 CMS
Alcon Vision LLC $3.9404/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650309 CMS
Novartis Pharmaceuticals Corporation $16.2103/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993363075 CMS
Alcon Vision LLC $22.6003/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650441 CMS
AbbVie Inc. $27.7503/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828777 CMS
AbbVie Inc. $675.0003/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828773 CMS
Alcon Vision LLC $24.4903/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650455 CMS
Beaver-Visitec International, Inc. $128.1003/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059223595 CMS
Nova Eye, Inc. $41.1003/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061068929 CMS
Glaukos Corporation $33.1403/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059867489 CMS
Bausch & Lomb Americas Inc. $32.9003/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037876117 CMS
Glaukos Corporation $33.3003/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059867487 CMS
Alcon Vision LLC $20.3603/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995650393 CMS
Glaukos Corporation $40.0803/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059867485 CMS
AbbVie Inc. $30.1602/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828769 CMS
AbbVie Inc. $21.9402/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828765 CMS
AbbVie Inc. $1,350.0002/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828761 CMS
Novartis Pharmaceuticals Corporation $15.1702/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993363073 CMS
AbbVie Inc. $5.1202/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828757 CMS
AbbVie Inc. $25.7501/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998828753 CMS
Glaukos Corporation $7.0701/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059853419 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $114,789.79 175
PY2020 $68,419.87 82
PY2021 $67,959.30 93
PY2022 $18,782.11 70
PY2023 $36,130.14 109
PY2024 $57,366.51 79
PY2025 $49,594.83 118

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,000.00 1
PY2025 Principal investigator $356,588.64 93
PY2024 Principal investigator $431,882.73 94
PY2023 Recipient $20,686.51 1
PY2023 Principal investigator $474,821.53 97
PY2022 Recipient $38,368.59 1
PY2022 Principal investigator $502,786.90 58
PY2021 Principal investigator $592,044.06 94
PY2020 Recipient $897.76 2
PY2020 Principal investigator $488,227.75 82
PY2019 Recipient $5.43 1
PY2019 Principal investigator $349,741.73 69

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

94 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $18,522.30 12/31/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202532516
Principal investigator 1 ABBVIE INC. $17,684.28 12/31/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202532518
Principal investigator 1 Glaukos Corporation $13,585.00 12/17/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911079
Principal investigator 1 Glaukos Corporation $2,550.00 12/10/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911021
Principal investigator 1 ABBVIE INC. $3,137.00 12/04/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202526750
Principal investigator 1 ABBVIE INC. $2,598.90 12/04/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202526844
Principal investigator 1 Glaukos Corporation $90.00 11/26/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910349
Principal investigator 1 Glaukos Corporation $700.00 11/26/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910529
Principal investigator 1 Glaukos Corporation $620.00 11/19/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911019
Principal investigator 1 Glaukos Corporation $22,465.00 11/19/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911077
Principal investigator 1 ABBVIE INC. $2,204.50 11/05/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202522899
Principal investigator 1 ABBVIE INC. $2,250.00 11/04/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202521099
Principal investigator 1 Glaukos Corporation $450.00 10/22/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910545
Principal investigator 1 Glaukos Corporation $400.00 10/22/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910557
Principal investigator 1 Glaukos Corporation $700.00 10/22/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910601
Principal investigator 1 ABBVIE INC. $5,776.90 10/09/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202513677
Principal investigator 1 ABBVIE INC. $4,788.45 10/09/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202513679
Principal investigator 1 ABBVIE INC. $2,028.00 10/09/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202513681
Principal investigator 1 Glaukos Corporation $2,550.00 10/08/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911017
Principal investigator 1 Glaukos Corporation $100.00 10/01/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910491
Principal investigator 1 ABBVIE INC. $936.85 09/18/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202511330
Principal investigator 1 Glaukos Corporation $100.00 09/17/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910707
Principal investigator 1 Glaukos Corporation $2,400.00 09/10/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911015
Principal investigator 1 Glaukos Corporation $5,690.00 09/10/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911075
Principal investigator 1 ABBVIE INC. $10,590.20 09/04/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202508596
Principal investigator 1 ABBVIE INC. $4,027.15 09/03/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202507229
Principal investigator 1 Glaukos Corporation $394.74 08/27/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903923
Principal investigator 1 Glaukos Corporation $14.52 08/13/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250902523
Principal investigator 1 Glaukos Corporation $59.12 08/13/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250902697
Principal investigator 1 Glaukos Corporation $450.00 08/13/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910753
Principal investigator 1 ABBVIE INC. $4,911.55 08/06/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202502498
Principal investigator 1 Glaukos Corporation $2,390.00 08/06/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911013
Principal investigator 1 Glaukos Corporation $1,860.00 08/06/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911073
Principal investigator 1 Glaukos Corporation $1,005.00 08/06/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250911177
Principal investigator 1 ABBVIE INC. $1,002.75 08/05/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202501408
Principal investigator 1 ABBVIE INC. $5,370.00 08/05/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202501410
Principal investigator 1 Glaukos Corporation $394.74 07/23/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903786
Principal investigator 1 Glaukos Corporation $800.00 07/16/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910683
Principal investigator 1 Glaukos Corporation $1,710.00 07/16/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910749
Principal investigator 1 ABBVIE INC. $2,344.80 07/02/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202494309
Principal investigator 1 ABBVIE INC. $1,215.50 07/02/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202494313
Principal investigator 1 Glaukos Corporation $1,550.00 07/02/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911011
Principal investigator 1 Glaukos Corporation $20,040.00 07/02/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911071
Recipient Ocular Therapeutix, Inc. $1,000.00 06/30/2025 Covered Recipient Physician A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) No dispute reported 06/30/2026 1250229403
Principal investigator 1 Glaukos Corporation $17.72 06/18/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903069
Principal investigator 1 Glaukos Corporation $3,950.00 06/18/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911003
Principal investigator 1 Glaukos Corporation $15.88 06/11/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903135
Principal investigator 1 Glaukos Corporation $517.24 06/04/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904052
Principal investigator 1 Glaukos Corporation $1,600.00 06/04/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910767
Principal investigator 1 Glaukos Corporation $3,680.00 06/04/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911009
Principal investigator 1 Glaukos Corporation $7,470.00 06/04/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911069
Principal investigator 1 Glaukos Corporation $2,010.00 06/04/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250911175
Principal investigator 1 ABBVIE INC. $6,442.00 06/03/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202488721
Principal investigator 1 ABBVIE INC. $1,643.00 06/03/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202488723
Principal investigator 1 Glaukos Corporation $197.37 05/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904166
Principal investigator 1 Glaukos Corporation $197.37 05/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904308
Principal investigator 1 Glaukos Corporation $114.84 05/14/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903345
Principal investigator 1 Glaukos Corporation $394.74 05/14/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904723
Principal investigator 1 Glaukos Corporation $1,480.00 05/07/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911007
Principal investigator 1 Glaukos Corporation $11,230.00 05/07/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911067
Principal investigator 1 Glaukos Corporation $3,215.00 05/07/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250911173
Principal investigator 1 ABBVIE INC. $575.00 05/06/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202482085
Principal investigator 1 ABBVIE INC. $4,594.00 05/06/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202482087
Principal investigator 1 Glaukos Corporation $270.00 04/29/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910731
Principal investigator 1 Glaukos Corporation $1,325.00 04/29/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910933
Principal investigator 1 ABBVIE INC. $8,165.25 04/03/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202471087
Principal investigator 1 ABBVIE INC. $3,232.00 04/03/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202471091
Principal investigator 1 Glaukos Corporation $517.24 04/02/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904598
Principal investigator 1 Glaukos Corporation $2,330.00 04/02/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911005
Principal investigator 1 Glaukos Corporation $14,305.00 04/02/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911065
Principal investigator 1 Glaukos Corporation $3,015.00 04/02/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250911169
Principal investigator 1 Glaukos Corporation $2,010.00 04/02/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250911171
Principal investigator 1 Glaukos Corporation $258.62 03/12/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904491
Principal investigator 1 Glaukos Corporation $400.00 03/12/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910901
Principal investigator 1 Glaukos Corporation $360.00 03/12/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910955
Principal investigator 1 ABBVIE INC. $21,708.65 03/06/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202457615
Principal investigator 1 ABBVIE INC. $1,643.00 03/06/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202457619
Principal investigator 1 Glaukos Corporation $4.67 03/05/2025 Non-covered Recipient Entity
Amazon.com, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250909565
Principal investigator 1 Glaukos Corporation $394.74 02/26/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250905122
Principal investigator 1 Glaukos Corporation $258.62 02/19/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904982
Principal investigator 1 ABBVIE INC. $2,502.02 02/13/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202451049
Principal investigator 1 Glaukos Corporation $4,945.00 02/12/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911001
Principal investigator 1 Glaukos Corporation $1,005.00 02/12/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250911167
Principal investigator 1 ABBVIE INC. $2,746.15 02/05/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202444253
Principal investigator 1 ABBVIE INC. $6,084.00 02/05/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202444257
Principal investigator 1 Glaukos Corporation $258.62 01/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904869
Principal investigator 1 Glaukos Corporation $258.62 01/08/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250905555
Principal investigator 1 Glaukos Corporation $90.00 01/08/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250910967
Principal investigator 1 Glaukos Corporation $44,190.00 01/08/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250910997
Principal investigator 1 Glaukos Corporation $92.53 01/08/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250910999
Principal investigator 1 Glaukos Corporation $1,500.00 01/08/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911063
Principal investigator 1 Glaukos Corporation $4,020.00 01/08/2025 Non-covered Recipient Entity
MIGS Consulting, LLC
iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study No dispute reported 06/30/2026 1250911165
Principal investigator 1 ABBVIE INC. $4,532.00 01/02/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1202433917
Principal investigator 1 ABBVIE INC. $2,365.50 01/02/2025 Non-covered Recipient Entity
MIGS CONSULTING LLC
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma No dispute reported 06/30/2026 1202433922